Atossa Therapeutics (ATOS) vs Immutep (IMMP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Immutep (IMMP) has outperformed Atossa Therapeutics (ATOS) over the past year, gaining 90.1% versus a loss of 85.5%. Over five years, IMMP leads with a -2.8% price change compared with -94.4% for ATOS. Immutep is the larger company by market cap ($26.3 million vs $24.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATOS | IMMP |
|---|---|---|
| Share price | $2.47 | $3.57 |
| Market cap | $24.68M | $26.31M |
| 1-day change | +2.19% | -7.03% |
| YTD return | -72.66% | +34.27% |
| 1-year return | -85.47% | +90.10% |
| 5-year return | -94.36% | -2.78% |
| EPS (TTM) | $-4.45 | $-7.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.00 | $70.60 |
| 52-week low | $1.70 | $3.55 |
| Distance from 52-week high | -86.26% | -94.94% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +668.27% | +740.34% |
| Average volume | 63.48K | 14.85K |
| Shares outstanding | 9.98M | 7.37M |
| Employees | 16 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMMP has outperformed ATOS by 175.6 percentage points over the past year.
About Atossa Therapeutics
ATOS stock →Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About Immutep
IMMP stock →Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations
ATOS vs IMMP FAQ
Which is bigger, Atossa Therapeutics or Immutep?
Immutep (IMMP) is larger, with a market capitalization of $26.31M compared with $24.68M for Atossa Therapeutics (ATOS).
Which stock has performed better over the past year, ATOS or IMMP?
IMMP returned +90.10% over the past 12 months, compared with -85.47% for ATOS (price return, excluding dividends). Past performance does not predict future results.
Are Atossa Therapeutics and Immutep in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.